التفاصيل البيبلوغرافية
| العنوان: |
Mechanisms underlying the compromised clinical efficacy of interferon in clearing HBV. |
| المؤلفون: |
Lei, Zhuoyan1 (AUTHOR), Wang, Luye1 (AUTHOR), Gao, Hanlin1 (AUTHOR), Guo, Shubian1 (AUTHOR), Kang, Xinjian1 (AUTHOR), Yuan, Jiajun1 (AUTHOR), Lv, Ziying1 (AUTHOR), Jiang, Yuxin1 (AUTHOR), Yi, Jinping2 (AUTHOR), Chen, Zhi3 (AUTHOR), Wang, Gang1 (AUTHOR) wg008@zjsru.edu.cn |
| المصدر: |
Virology Journal. 12/4/2024, Vol. 21 Issue 1, p1-13. 13p. |
| مصطلحات موضوعية: |
*CHRONIC hepatitis B, *CHRONIC active hepatitis, *MEDICAL sciences, *HEPATITIS B virus, *MEDICAL microbiology, *LAMIVUDINE |
| مستخلص: |
Hepatitis B virus (HBV) is a hepatotropic DNA virus that can cause acute or chronic hepatitis, representing a significant global health concern. By 2019, approximately 296 million individuals were chronically infected with HBV, with 1.5 million new cases annually and 820,000 deaths due to HBV-related cirrhosis and liver cancer. Current treatments for chronic hepatitis B include nucleotide analogs (NAs) and interferons (IFNs), particularly IFN-α. NAs, such as entecavir and tenofovir, inhibit viral reverse transcription, while IFN-α exerts antiviral effects by directly suppressing viral replication, modulating viral genome epigenetics, degrading cccDNA, and activating immune responses. Despite its potential, IFN-α shows limited clinical efficacy, partly due to HBV's interference with the IFN signaling pathway. HBV encodes proteins like HBc, Pol, HBsAg, and HBx that disrupt IFN-α function. For example, HBV Pol inhibits STAT1 phosphorylation, HBsAg suppresses STAT3 phosphorylation, and HBx interferes with IFN-α efficacy through multiple mechanisms. Additionally, HBV downregulates key genes in the IFN signaling pathway, further diminishing IFN-α's antiviral effects. Understanding these interactions is crucial for improving IFN-α-based therapies. Future research may focus on overcoming HBV resistance by targeting viral proteins or optimizing IFN-α delivery. In summary, HBV's ability to resist IFN-α limits its therapeutic effectiveness, highlighting the need for new strategies to enhance treatment outcomes. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder